Bio-Rad extends range of anti-idiotypic antibodies for bioanalysis, drug monitoring

By The Science Advisory Board staff writers

July 12, 2022 -- Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin (Adcetris), secukinumab (Cosentyx), and the secukinumab-interleukin 17A (IL-17A) drug-target complex.

Brentuximab vedotin is an antibody drug conjugate used to treat Hodgkin lymphoma, and secukinumab is used to inhibit a patient's inflammatory response in several diseases, including ankylosing spondylitis, psoriasis, and psoriatic arthritis. Bio-Rad's new, highly specific antibodies can be used in the bioanalysis and drug monitoring of brentuximab vedotin, secukinumab, as well as their biosimilars.

The antibrentuximab vedotin and antisecukinumab antibodies are approved for in vitro research purposes, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and for patient monitoring.

Protein crystallography links rigid antibody hinges to increased anticancer activity
Researchers at the University of Southampton have gained new insight into the key properties of an antibody needed to fight off cancer using protein crystallography,...
Researchers capture images of antibody attacking neuron receptor
U.S. and German researchers have captured the first images of an antibody attacking a nerve cell surface receptor using cryo-electron microscopy, a technique...
Bio-Rad develops antidaratumumab antibodies for drug monitoring
Bio-Rad Laboratories has launched a range of antidaratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter